# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:CAPR) with a Outperform and raises the price tar...
Maxim Group analyst Jason McCarthy reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $12 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...
The biotechnology company said deramiocel increased cardiac function based on several different measures.
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patient...